The TEAD4 antibody is a crucial tool in studying the TEAD family of transcription factors, specifically targeting TEAD4 (TEA Domain Transcription Factor 4), a key regulator in the Hippo signaling pathway. TEAD proteins bind to DNA through conserved TEA/ATTS domains and interact with coactivators like YAP/TAZ to control gene expression involved in cell proliferation, survival, and organ development. TEAD4. in particular, plays a significant role in embryonic development, tissue regeneration, and cancer progression. It is overexpressed in multiple cancers, including colorectal, ovarian, and prostate cancer, where it promotes tumor growth and metastasis by activating oncogenic pathways.
The TEAD4 antibody is widely used in research to detect TEAD4 protein levels and localization via techniques such as Western blotting, immunohistochemistry, and immunofluorescence. It helps elucidate TEAD4’s interaction with YAP/TAZ, its regulatory mechanisms, and its role in Hippo pathway dysregulation. Commercially available antibodies are typically validated for specificity, often targeting epitopes within the N-terminal or C-terminal regions. Studies using TEAD4 antibodies have contributed to understanding its dual role in development and disease, highlighting its potential as a therapeutic target. Inhibitors disrupting TEAD4-YAP/TAZ interactions are under investigation for cancer treatment, underscoring the antibody’s importance in both basic and translational research.